Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer

HER2-mutant Non-Small Cell Lung Cancer Clinical Trial

Official title:

A Phase 2 Study of Neratinib and Neratinib Plus Temsirolimus in Patients With Non-Small Cell Lung Cancer Carrying Known HER2 Activating Mutations

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01827267
• Other study ID #: PUMA-NER-4201
• Secondary ID: 2012-004743-68
• Status: Completed
• Phase: Phase 2
• Start date: July 1, 2013
• Est. completion date: October 6, 2017

Study information

• Verified date: May 2018
• Source: Puma Biotechnology, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 2, therapeutic-exploratory, adaptive design, open-label, multicenter, multinational study evaluating neratinib monotherapy and neratinib plus temsirolimus combination therapy in patients with non-small cell lung cancer (NSCLC) who have documented somatic HER2 mutations.

Description:

This is a Phase 2, therapeutic-exploratory, adaptive design, open-label, multicenter, multinational study evaluating neratinib monotherapy and neratinib plus temsirolimus combination therapy in patients with NSCLC and documented somatic HER2 mutations. Patients randomized at study entry into 1 of 2 treatment arms:

• Arm A: neratinib 240 mg orally once daily

• Arm B: neratinib 240 mg orally once daily plus temsirolimus 8 mg once weekly by intravenous (IV) infusion

In the case of disease progression, patients initially assigned to neratinib monotherapy arm given option to add temsirolimus 8 mg IV once weekly.

Patients on combination therapy given option to dose-escalate temsirolimus to 15 mg/week at the end of first cycle of treatment, if well tolerated and at the physician's discretion. If neratinib 240 mg/day plus temsirolimus 15 mg/week dose not well tolerated, patient subsequently dose reduced back to neratinib 240 mg/day plus temsirolimus 8 mg/week.

Dosing continuous on nominal 3-week cycles until evidence of progressive disease, unacceptable toxicity, or patient withdrawal of consent.

Disease measured radiographically at baseline and every 6 weeks until disease progression or withdrawal from the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 62
• Est. completion date: October 6, 2017
• Est. primary completion date: September 20, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

1. Aged =18 years at the time of signing the informed consent.

2. Histologically confirmed diagnosis of NSCLC, advanced (stage IIIB) or metastatic (stage IV).

3. Documented somatic ErbB2 (HER2) activating mutation.

4. Patients with anaplastic lymphoma kinase (ALK) translocations must have received crizotinib, except for cases of intolerable toxicity to crizotinib.

5. At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).

6. Eastern Cooperative Oncology Group (ECOG) status <2.

7. Left ventricular ejection fraction (LVEF) =50% measured by multiple -gated acquisition scan (MUGA) or echocardiogram (ECHO).

8. Negative ß-human chorionic gonadotropin (hCG) pregnancy test for premenopausal women of reproductive capacity (those who are biologically capable of having children) and for women less than 12 months after menopause.

9. Men and women of childbearing potential must agree and commit to the use of a highly effective method of contraception, as determined to be acceptable by the Investigator, from the time of informed consent until 3 months after the last dose of the investigational products.

10. Provide written, informed consent to participate in the study and follow the study procedures.

Exclusion Criteria

1. Previous treatment with any investigational agent =14 days prior to the initiation of investigational products.

2. Previous treatment with any strong inhibitor and/or inducer of CYP3A4 enzyme or sensitive P-glycoprotein (P-gp) substrates =30 days prior to the initiation of investigational products.

3. Active uncontrolled cardiac disease, including cardiomyopathy, congestive heart failure (New York Heart Association functional classification of =2), unstable angina, myocardial infarction within 12 months of enrollment, or ventricular arrhythmia.

4. Major surgery <30 days of starting treatment.

5. Chronic steroid use (prednisone >12.5 mg/day or dexamethasone >2 mg/day, excluding inhaled steroids).

6. Currently breast feeding.

7. Symptomatic or unstable brain metastases.

8. QTc interval >0.450 seconds for men and >0.470 seconds for women, or known history of QTc prolongation or Torsades de Pointes (TdP).

9. Significant chronic gastrointestinal disorder with diarrhea as a major symptom (e.g., Crohn's disease, malabsorption, or Grade =2 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events Version 4.0 [CTCAE v.4.0] diarrhea of any etiology at baseline).

10. Prior exposure to neratinib or mTOR inhibitor.

11. Active infection or unexplained fever >38.5°C (101.3°F).

12. Unable or unwilling to swallow tablets.

13. Evidence of significant medical illness, abnormal laboratory finding, or psychiatric illness/social situations that would, in the Investigator's judgment, make the patient inappropriate for this study.

14. Known hypersensitivity to any component of the investigational products.

15. Unstable or uncontrolled diabetes mellitus (glycosylated hemoglobin [HbA1c] >6.5%).

16. Screening laboratory assessments outside the following limits: ANC <1000/µL (<1.0 x 109/L), Platelet count <75,000/µL (<75 x 109/L), Hemoglobin <8 g/dL, transfusions allowed, must be at least 7 days prior to baseline, Total bilirubin >1.5 x institutional upper limit of normal (ULN), AST and/or ALT 5 minutes, Creatinine clearance <50 mL/min.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• HER2-mutant Non-Small Cell Lung Cancer
• Lung Neoplasms

Intervention

Drug:
• neratinib

• temsirolimus

Locations

Country	Name	City	State
France	CHU de Grenoble Hopital Albert Michallon	Grenoble
France	CHRU de Lille - Hopital Calmette	Lille
France	Hopital Nord	Marseille
France	Hopitaux universitaires de Strasbourg Nouvel Hopital Civil	Strasbourg
France	CHU de Toulous Hopital Larre	Toulouse
France	Institut Gustave Roussy	Villejuif
United States	University of Colorado	Aurora	Colorado
United States	Johns Hopkins	Baltimore	Maryland
United States	Beth Israel Deaconess Medical Center	Boston	Massachusetts
United States	Dana Farber Cancer Institute	Boston	Massachusetts
United States	Massachusettes General Hospital	Boston	Massachusetts
United States	Ohio State University	Columbus	Ohio
United States	UT Southwestern Medical Center	Dallas	Texas
United States	City of Hope	Duarte	California
United States	MD Anderson Cancer Center	Houston	Texas
United States	Vanderbilt University	Nashville	Tennessee
United States	Memorial Sloan-Kettering Cancer Center	New York	New York
United States	University of Pittsburgh Cancer Institute	Pittsburgh	Pennsylvania
United States	Washington University School of Medicine	Saint Louis	Missouri
United States	University of California Los Angeles	Santa Monica	California
United States	Moffitt Cancer Center	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Puma Biotechnology, Inc.

Countries where clinical trial is conducted

United States,  France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate (ORR)	ORR is defined as proportion of subjects who achieved confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.1: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.; A complete or partial response must be confirmed no less than 4-weeks after the criteria for response are initially met.	From randomization to last tumor assessment, assessed up to 116.5 weeks. For the Neratinib arm, only tumor assessments prior to crossover were included.
Secondary	Clinical Benefit Rate (CBR)	CBR is defined as the proportion of patients who achieved objective response (CR or PR) or stable disease (SD) for at least 12 weeks.	From randomization to last tumor assessment, assessed up to 116.5 weeks. For the Neratinib arm, only tumor assessments prior to crossover were included.
Secondary	Duration of Response (DOR)	Measured from the time at which measurement criteria were first met for CR or PR (whichever status was recorded first), until the date of first recurrence, progressive disease (PD), or death was objectively documented, taking as a reference for PD the smallest measurements recorded since enrollment, per RECIST (v1.1) criteria.	From randomization to last tumor assessment, assessed up to 116.5 weeks. For the Neratinib arm, only tumor assessments prior to crossover were included.
Secondary	Progression Free Survival (PFS)	Defined as time from date of randomization until the first disease recurrence or progression per RECIST V1.1 or death due to any cause; censored at the last assessable evaluation or at the initiation of new anti-cancer therapy. Disease assessment is based on investigator tumor assessments. If no post-baseline tumor assessment then censored at enrollment date.	From randomization to last tumor assessment, assessed up to 116.5 weeks. For the Neratinib arm, only tumor assessments prior to crossover were included.
Secondary	Overall Survival (OS)	Defined as the time (month) from randomization to death due to any cause; censored at the date last known alive.	From randomization to death or end of long term follow-up, assessed up to 31.8 months.